SHORT COMMUNICATION
Standards of treatment
of the National Consultant for Rheumatology standpoint for the biologic therapy of juvenile idiopathic arthritis
of the National Consultant for Rheumatology standpoint for the biologic therapy of juvenile idiopathic arthritis
Online publication date: 2009-08-11
Reumatologia 2009;47(3):111-115
KEYWORDS
ABSTRACT
Juvenile idiopathic arthritis (JIA) is the most common chronic autoimmune disease in children. Treatment relies mostly on nonsteroidal anti-inflammatory drugs, corticosteroids, and disease – modyfying antirheumatic drugs. “Biologics” (anticytokine drugs) are an important therapeutic option for treating patients with JIA and will be introduced as therapy in the course of patients, who inadequately respond to conventional disease-modyfying antirheumatic drugs, preferred methotrexate. In the publication we present the position of the expert pediatric rheumatologist panel of the National Consultant for Rheumatology concerning anticytokine drugs in JIA treatment.
REFERENCES (24)
1.
Petty RE, Southwood TR, Manners P, et al.; International League of Associations for Rheumatology. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J Rheumatol 2004; 31: 390-392. .
2.
Symmons DP, Jones M, Osborne J, et al. Pediatric rheumatology in the United Kingdom: data from the British Pediatric Rheumatology Group National Diagnostic Register. J Rheumatol 1996; 23: 1975-1980. .
3.
von Koskull S, Truckenbrodt H, Holle R, Hörmann A. Incidence and prevalence of juvenile arthritis in an urban population of southern Germany: a prospective study. Ann Rheum Dis 2001; 60: 940-945. .
4.
Danner S, Sordet C, Terzic J, et al. Epidemiology of juvenile idiopathic arthritis in Alsace, France. J Rheumatol 2006; 33: 1377-1381. .
5.
Wolny-Niedzielska A. Choroby układu ruchu u dzieci kierowanych do Poradni Reumatologicznej w Kielcach w latach 1999–2003. Reumatologia 2005; 43: 265-273. .
6.
Zygmunt A, Biernacka-Zielińska M, Brózik H i wsp. Choroby reumatyczne w populacji dzieci i młodzieży z regionu łódzkiego. Ped Pol 2005; 80: 995-1001. .
7.
Packham JC, Hall MA. Long-term follow-up of 246 adults with juvenile idiopathic arthritis: functional outcome. Rheumatology (Oxford) 2002; 41: 1428-1435. .
8.
Zak M, Pedersen F. Juvenile chronic arthritis into adulthood: a long-term follow-up study. Rheumatology (Oxford) 2000; 39: 198-204. .
9.
Lovell DJ, Ruperto N, Goodman S, et al.; Pediatric Rheumatology Collaborative Study Group; Pediatric Rheumatology International Trials Organisation. Adalimumab with or without methotrexate in juvenile rheumatoid arthritis. N Engl J Med 2008; 359: 2495-2497. .
10.
Lovell DJ, Reiff A, Ilowite NT, et al.; Pediatric Rheumatology Collaborative Study Group. Safety and efficacy of up to eight years of continuous etanercept therapy in patients with juvenile rheumatoid arthritis. Arthritis Rheum 2008; 58: 1496-1504. .
11.
Paller AS, Siegfried EC, Langley RG, et al.; Etanercept Pediatric Psoriasis Study Group. Etanercept treatment for children and adolescents with plaque psoriasis. N Engl J Med 2008; 358: 241-251. .
12.
Prince FH, Twilt M, ten Cate R, et al. Long-term follow-up on effectiveness and safety of etanercept in JIA: the Dutch national register. Ann Rheum Dis 2009; 68: 635-641. .
13.
Horneff G, De Bock F, Foeldvari I, et al.; German and Austrian Paediatric Rheumatology Collaborative Study Group. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA). Preliminary data from the German JIA Registry. Ann Rheum Dis 2009; 68: 519-525. .
14.
Simonini G, Giani T, Stagi S, et al. Bone status over 1 yr of etanercept treatment in juvenile idiopathic arthritis. Rheumatology (Oxford) 2005; 44: 777-780. .
15.
Tynjälä P, Lahdenne PL, Vähäsalo P, et al. Impact of anti-TNF treatment on growth in severe juvenile idiopathic arthritis. Ann Rheum Dis 2006; 65: 1044-1049. .
16.
Tzaribachev N, Kuemmerle-Deschner J, Eichner M, Horneff G. Safety and efficacy of etanercept in children with juvenile idiopathic arthritis below the age of 4 years. Rheumatol Int 2008; 28: 1031-1034. .
17.
Kuemmerle-Deschner JB, Horneff G. Safety and efficacy of once-weekly application of Etanercept in children with juvenile idiopathic arthritis. Rheumatol Int 2007; 28: 153-156. .
18.
Prince FH, Twilt M, Jansen-Wijngaarden NC, van Suijlekom-Smit LW. Effectiveness of a once weekly double dose of etanercept in patients with juvenile idiopathic arthritis: a clinical study. Ann Rheum Dis 2007; 66: 704-705. .
19.
Tynjäla P, Kotaniemi K, Lindahl P, et al. Adalimumab in juvenile idiopathic arthritis-associated chronic anterior uveitis. Rheumatology (Oxford) 2008; 47: 339-344. .
20.
Mansour AM. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol 2007; 91: 274-276. .
21.
Guidance on the use of etanercept for the treatment of juvenile idiopathic arthritis. NICE Technology Appraisal Guidance – No. 35, March 2002. .
22.
Romicka AM, Ruperto N, Gutowska-Grzegorczyk G, et al.; Paediatric Rheumatology International Trials Organisation. The Polish version of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ). Clin Exp Rheumatol 2001; 19 (4 Suppl 23): S121-S125. .
23.
Giannini EH, Ruperto N, Ravelli A, et al. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40; 1202-1209. .
24.
Wallace CA, Ruperto N, Giannini E; Childhood Arthritis and Rheumatology Research Alliance; Pediatric Rheumatology International Trials Organization; Pediatric Rheumatology Collaborative Study Group. Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis. J Rheumatol 2004; 31: 2290-2294.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Share
RELATED ARTICLE
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
